Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-09

AUTHORS

B. Uebelhart, R. Rizzoli, S. L. Ferrari

ABSTRACT

Discontinuation of denosumab (Dmab) therapy is associated with lower serum CTX levels in osteoporotic patients previously exposed to bisphosphonates compared to those who were not. INTRODUCTION: Discontinuation of Dmab therapy is followed by a transient increase of bone turnover markers (BTMs) above pretreatment values, together with accelerated bone loss, and potentially an increased risk of multiple vertebral fractures. Since a substantial proportion of patients discontinuing Dmab have previously been exposed to bisphosphonates (BPs), we hypothesized that previous BP therapy could attenuate this increase in bone turnover because of the prolonged biological effects of BPs on bone. METHODS: In a retrospective observation, we assessed serum CTX levels between 7 and 24 months after the last Dmab injection in 37 patients (33 women and 4 men, aged 50 to 84 years). CTX levels were analyzed according to the number of Dmab injections (1 or multiple) and previous exposure to BPs. RESULTS: In 8 patients who had received only 1 Dmab injection, 7 out of 8 were previously on BPs and none of them showed CTX values above the premenopausal range after Dmab discontinuation. CTX also remained in the premenopausal range in 14 out of 17 patients who discontinued Dmab after multiple (4.1 ± 1.4, range 2-7) injections but were previously exposed to BPs (mean exposure 6.9 ± 5.8 years, range 11 months-15 years; mean time interval between BP exposure and Dmab initiation 25 ± 10 months, range 0-48). In contrast, in 12 patients who discontinued Dmab after multiple (5, range 3-9) injections without prior exposure to BPs, mean CTX levels as measured on average 11.3 months (range 6-23) after the last Dmab injection were above the upper limit of premenopausal range (mean +114%, range 28-320%, p = 0.003-0.005 vs previous BPs). CONCLUSION: The higher CTX levels occurring after Dmab discontinuation in patients who have received multiple injections may be prevented by prior exposure to BPs. This observation may be related to the persistent effects of BPs on bone that prevent the resorbing activity of newly formed osteoclasts when RANK Ligand is no more antagonized. More... »

PAGES

2701-2705

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00198-017-4080-6

DOI

http://dx.doi.org/10.1007/s00198-017-4080-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1085573618

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28540505


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density Conservation Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Remodeling", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Collagen Type I", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Denosumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deprescriptions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diphosphonates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Osteoporosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Peptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Withholding Treatment", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University Hospital of Geneva", 
          "id": "https://www.grid.ac/institutes/grid.150338.c", 
          "name": [
            "Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland", 
            "Service des Maladies Osseuses, H\u00f4pitaux Universitaires et Facult\u00e9 de M\u00e9decine de Gen\u00e8ve, 1211, Geneva 14, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Uebelhart", 
        "givenName": "B.", 
        "id": "sg:person.01170462732.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170462732.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Hospital of Geneva", 
          "id": "https://www.grid.ac/institutes/grid.150338.c", 
          "name": [
            "Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rizzoli", 
        "givenName": "R.", 
        "id": "sg:person.01117504756.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117504756.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University Hospital of Geneva", 
          "id": "https://www.grid.ac/institutes/grid.150338.c", 
          "name": [
            "Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ferrari", 
        "givenName": "S. L.", 
        "id": "sg:person.010316207732.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010316207732.14"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.bone.2008.04.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010244282"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0809493", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010400337"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-015-3459-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014122819", 
          "https://doi.org/10.1007/s00198-015-3459-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.296.24.2927", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015996674"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jbmr.2442", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016639991"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0002-9343(97)00249-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023314389"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jc.2016-3170", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027079529"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-015-3458-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033563787", 
          "https://doi.org/10.1007/s00198-015-3458-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-015-3380-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036221276", 
          "https://doi.org/10.1007/s00198-015-3380-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jbmr.1808", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036886575"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1359/jbmr.040305", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040664727"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmc062792", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046528061"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-017-3919-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083400111", 
          "https://doi.org/10.1007/s00198-017-3919-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-017-3919-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083400111", 
          "https://doi.org/10.1007/s00198-017-3919-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jbmr.3110", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084012872"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-09", 
    "datePublishedReg": "2017-09-01", 
    "description": "Discontinuation of denosumab (Dmab) therapy is associated with lower serum CTX levels in osteoporotic patients previously exposed to bisphosphonates compared to those who were not.\nINTRODUCTION: Discontinuation of Dmab therapy is followed by a transient increase of bone turnover markers (BTMs) above pretreatment values, together with accelerated bone loss, and potentially an increased risk of multiple vertebral fractures. Since a substantial proportion of patients discontinuing Dmab have previously been exposed to bisphosphonates (BPs), we hypothesized that previous BP therapy could attenuate this increase in bone turnover because of the prolonged biological effects of BPs on bone.\nMETHODS: In a retrospective observation, we assessed serum CTX levels between 7 and 24\u00a0months after the last Dmab injection in 37 patients (33 women and 4 men, aged 50 to 84\u00a0years). CTX levels were analyzed according to the number of Dmab injections (1 or multiple) and previous exposure to BPs.\nRESULTS: In 8 patients who had received only 1 Dmab injection, 7 out of 8 were previously on BPs and none of them showed CTX values above the premenopausal range after Dmab discontinuation. CTX also remained in the premenopausal range in 14 out of 17 patients who discontinued Dmab after multiple (4.1\u00a0\u00b1\u00a01.4, range 2-7) injections but were previously exposed to BPs (mean exposure 6.9\u00a0\u00b1\u00a05.8\u00a0years, range 11\u00a0months-15\u00a0years; mean time interval between BP exposure and Dmab initiation 25\u00a0\u00b1\u00a010\u00a0months, range 0-48). In contrast, in 12 patients who discontinued Dmab after multiple (5, range 3-9) injections without prior exposure to BPs, mean CTX levels as measured on average 11.3\u00a0months (range 6-23) after the last Dmab injection were above the upper limit of premenopausal range (mean +114%, range 28-320%, p\u00a0=\u00a00.003-0.005 vs previous BPs).\nCONCLUSION: The higher CTX levels occurring after Dmab discontinuation in patients who have received multiple injections may be prevented by prior exposure to BPs. This observation may be related to the persistent effects of BPs on bone that prevent the resorbing activity of newly formed osteoclasts when RANK Ligand is no more antagonized.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00198-017-4080-6", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100834", 
        "issn": [
          "0937-941X", 
          "1433-2965"
        ], 
        "name": "Osteoporosis International", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "28"
      }
    ], 
    "name": "Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates", 
    "pagination": "2701-2705", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "803e924010a0a13011d8e367ddc0e085eec2496e9b4eaf73bf7f927bec58836f"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28540505"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9100105"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00198-017-4080-6"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1085573618"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00198-017-4080-6", 
      "https://app.dimensions.ai/details/publication/pub.1085573618"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89819_00000003.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00198-017-4080-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00198-017-4080-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00198-017-4080-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00198-017-4080-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00198-017-4080-6'


 

This table displays all metadata directly associated to this object as RDF triples.

206 TRIPLES      21 PREDICATES      62 URIs      40 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00198-017-4080-6 schema:about N18d02a66aeec4ad2a6f5a232a3c95636
2 N21493dcf3ccb4513b2df8269480abc81
3 N2158fa2ebebc424fa39bb25d2cdf38a9
4 N2e8f77c885b1400794d1f90d9e55a429
5 N339f1ca7567c4560b3a966f462c5da97
6 N3c7c19e878af42c68ef89ba55fa8d73b
7 N3f4a6893d4a3446ca78e41857b8e0dd8
8 N657afae2daa84df8a50402129b553b5d
9 N68a6769a40b64cafbb949e0c9cf5ae84
10 N7a9f557e06f3432890b50d524fd865ed
11 N7e9d2c52b1e9477ca28016e25568d022
12 N8278b048e3684f45800018d7dca2e53a
13 N85a0d392e17944e4b654c6aad96c28fb
14 N8a5734f142c44f04ab94be6dbbbcb5fa
15 Na40363c01aca453180edbf028bc8a37f
16 Nb538603283784523a9f00bc39404e8b2
17 Nbd579bc15e6641da89e037e2184489a9
18 Nd12d8e33afa54ec987fe06352861cd9c
19 Nfafdf2bf4eb54ee88e3f4212c797c361
20 anzsrc-for:11
21 anzsrc-for:1103
22 schema:author N4031b0d196ba43aea875ade0c0863114
23 schema:citation sg:pub.10.1007/s00198-015-3380-y
24 sg:pub.10.1007/s00198-015-3458-6
25 sg:pub.10.1007/s00198-015-3459-5
26 sg:pub.10.1007/s00198-017-3919-1
27 https://doi.org/10.1001/jama.296.24.2927
28 https://doi.org/10.1002/jbmr.1808
29 https://doi.org/10.1002/jbmr.2442
30 https://doi.org/10.1002/jbmr.3110
31 https://doi.org/10.1016/j.bone.2008.04.007
32 https://doi.org/10.1016/s0002-9343(97)00249-0
33 https://doi.org/10.1056/nejmc062792
34 https://doi.org/10.1056/nejmoa0809493
35 https://doi.org/10.1210/jc.2016-3170
36 https://doi.org/10.1359/jbmr.040305
37 schema:datePublished 2017-09
38 schema:datePublishedReg 2017-09-01
39 schema:description Discontinuation of denosumab (Dmab) therapy is associated with lower serum CTX levels in osteoporotic patients previously exposed to bisphosphonates compared to those who were not. INTRODUCTION: Discontinuation of Dmab therapy is followed by a transient increase of bone turnover markers (BTMs) above pretreatment values, together with accelerated bone loss, and potentially an increased risk of multiple vertebral fractures. Since a substantial proportion of patients discontinuing Dmab have previously been exposed to bisphosphonates (BPs), we hypothesized that previous BP therapy could attenuate this increase in bone turnover because of the prolonged biological effects of BPs on bone. METHODS: In a retrospective observation, we assessed serum CTX levels between 7 and 24 months after the last Dmab injection in 37 patients (33 women and 4 men, aged 50 to 84 years). CTX levels were analyzed according to the number of Dmab injections (1 or multiple) and previous exposure to BPs. RESULTS: In 8 patients who had received only 1 Dmab injection, 7 out of 8 were previously on BPs and none of them showed CTX values above the premenopausal range after Dmab discontinuation. CTX also remained in the premenopausal range in 14 out of 17 patients who discontinued Dmab after multiple (4.1 ± 1.4, range 2-7) injections but were previously exposed to BPs (mean exposure 6.9 ± 5.8 years, range 11 months-15 years; mean time interval between BP exposure and Dmab initiation 25 ± 10 months, range 0-48). In contrast, in 12 patients who discontinued Dmab after multiple (5, range 3-9) injections without prior exposure to BPs, mean CTX levels as measured on average 11.3 months (range 6-23) after the last Dmab injection were above the upper limit of premenopausal range (mean +114%, range 28-320%, p = 0.003-0.005 vs previous BPs). CONCLUSION: The higher CTX levels occurring after Dmab discontinuation in patients who have received multiple injections may be prevented by prior exposure to BPs. This observation may be related to the persistent effects of BPs on bone that prevent the resorbing activity of newly formed osteoclasts when RANK Ligand is no more antagonized.
40 schema:genre research_article
41 schema:inLanguage en
42 schema:isAccessibleForFree false
43 schema:isPartOf N915783c455884be586762105eb7e2011
44 Nfe165ffcb2ea476488d38e340c39dbda
45 sg:journal.1100834
46 schema:name Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates
47 schema:pagination 2701-2705
48 schema:productId N0b7f0c9430d74327927bf7130ad76647
49 N3649e469ace9433ca0ddc6544201f259
50 N85ffa364da544af385722a0b2b9f35ed
51 Ne620c5811f7e4a1696f642c3cdbfae8c
52 Nfbf401f3a09f4f8698e2798978379ba6
53 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085573618
54 https://doi.org/10.1007/s00198-017-4080-6
55 schema:sdDatePublished 2019-04-11T10:01
56 schema:sdLicense https://scigraph.springernature.com/explorer/license/
57 schema:sdPublisher Ndf1cc18908934df889e3a750e20d28e3
58 schema:url https://link.springer.com/10.1007%2Fs00198-017-4080-6
59 sgo:license sg:explorer/license/
60 sgo:sdDataset articles
61 rdf:type schema:ScholarlyArticle
62 N0b7f0c9430d74327927bf7130ad76647 schema:name dimensions_id
63 schema:value pub.1085573618
64 rdf:type schema:PropertyValue
65 N16bdab993dba4f99a6cf28ab60a40e83 rdf:first sg:person.010316207732.14
66 rdf:rest rdf:nil
67 N18d02a66aeec4ad2a6f5a232a3c95636 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Collagen Type I
69 rdf:type schema:DefinedTerm
70 N21493dcf3ccb4513b2df8269480abc81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Deprescriptions
72 rdf:type schema:DefinedTerm
73 N2158fa2ebebc424fa39bb25d2cdf38a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Drug Therapy, Combination
75 rdf:type schema:DefinedTerm
76 N2e8f77c885b1400794d1f90d9e55a429 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Female
78 rdf:type schema:DefinedTerm
79 N339f1ca7567c4560b3a966f462c5da97 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Bone Density Conservation Agents
81 rdf:type schema:DefinedTerm
82 N3649e469ace9433ca0ddc6544201f259 schema:name readcube_id
83 schema:value 803e924010a0a13011d8e367ddc0e085eec2496e9b4eaf73bf7f927bec58836f
84 rdf:type schema:PropertyValue
85 N3c7c19e878af42c68ef89ba55fa8d73b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Peptides
87 rdf:type schema:DefinedTerm
88 N3f4a6893d4a3446ca78e41857b8e0dd8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Withholding Treatment
90 rdf:type schema:DefinedTerm
91 N4031b0d196ba43aea875ade0c0863114 rdf:first sg:person.01170462732.61
92 rdf:rest Nfdf9c7b28cfb465d92a3e6ab3be0ff3b
93 N657afae2daa84df8a50402129b553b5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Aged
95 rdf:type schema:DefinedTerm
96 N68a6769a40b64cafbb949e0c9cf5ae84 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Osteoporosis
98 rdf:type schema:DefinedTerm
99 N7a9f557e06f3432890b50d524fd865ed schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Male
101 rdf:type schema:DefinedTerm
102 N7e9d2c52b1e9477ca28016e25568d022 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Middle Aged
104 rdf:type schema:DefinedTerm
105 N8278b048e3684f45800018d7dca2e53a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Biomarkers
107 rdf:type schema:DefinedTerm
108 N85a0d392e17944e4b654c6aad96c28fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Drug Administration Schedule
110 rdf:type schema:DefinedTerm
111 N85ffa364da544af385722a0b2b9f35ed schema:name pubmed_id
112 schema:value 28540505
113 rdf:type schema:PropertyValue
114 N8a5734f142c44f04ab94be6dbbbcb5fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Diphosphonates
116 rdf:type schema:DefinedTerm
117 N915783c455884be586762105eb7e2011 schema:issueNumber 9
118 rdf:type schema:PublicationIssue
119 Na40363c01aca453180edbf028bc8a37f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Bone Remodeling
121 rdf:type schema:DefinedTerm
122 Nb538603283784523a9f00bc39404e8b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Humans
124 rdf:type schema:DefinedTerm
125 Nbd579bc15e6641da89e037e2184489a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Aged, 80 and over
127 rdf:type schema:DefinedTerm
128 Nd12d8e33afa54ec987fe06352861cd9c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Denosumab
130 rdf:type schema:DefinedTerm
131 Ndf1cc18908934df889e3a750e20d28e3 schema:name Springer Nature - SN SciGraph project
132 rdf:type schema:Organization
133 Ne620c5811f7e4a1696f642c3cdbfae8c schema:name doi
134 schema:value 10.1007/s00198-017-4080-6
135 rdf:type schema:PropertyValue
136 Nfafdf2bf4eb54ee88e3f4212c797c361 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Retrospective Studies
138 rdf:type schema:DefinedTerm
139 Nfbf401f3a09f4f8698e2798978379ba6 schema:name nlm_unique_id
140 schema:value 9100105
141 rdf:type schema:PropertyValue
142 Nfdf9c7b28cfb465d92a3e6ab3be0ff3b rdf:first sg:person.01117504756.04
143 rdf:rest N16bdab993dba4f99a6cf28ab60a40e83
144 Nfe165ffcb2ea476488d38e340c39dbda schema:volumeNumber 28
145 rdf:type schema:PublicationVolume
146 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
147 schema:name Medical and Health Sciences
148 rdf:type schema:DefinedTerm
149 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
150 schema:name Clinical Sciences
151 rdf:type schema:DefinedTerm
152 sg:journal.1100834 schema:issn 0937-941X
153 1433-2965
154 schema:name Osteoporosis International
155 rdf:type schema:Periodical
156 sg:person.010316207732.14 schema:affiliation https://www.grid.ac/institutes/grid.150338.c
157 schema:familyName Ferrari
158 schema:givenName S. L.
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010316207732.14
160 rdf:type schema:Person
161 sg:person.01117504756.04 schema:affiliation https://www.grid.ac/institutes/grid.150338.c
162 schema:familyName Rizzoli
163 schema:givenName R.
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01117504756.04
165 rdf:type schema:Person
166 sg:person.01170462732.61 schema:affiliation https://www.grid.ac/institutes/grid.150338.c
167 schema:familyName Uebelhart
168 schema:givenName B.
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01170462732.61
170 rdf:type schema:Person
171 sg:pub.10.1007/s00198-015-3380-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1036221276
172 https://doi.org/10.1007/s00198-015-3380-y
173 rdf:type schema:CreativeWork
174 sg:pub.10.1007/s00198-015-3458-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033563787
175 https://doi.org/10.1007/s00198-015-3458-6
176 rdf:type schema:CreativeWork
177 sg:pub.10.1007/s00198-015-3459-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014122819
178 https://doi.org/10.1007/s00198-015-3459-5
179 rdf:type schema:CreativeWork
180 sg:pub.10.1007/s00198-017-3919-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083400111
181 https://doi.org/10.1007/s00198-017-3919-1
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1001/jama.296.24.2927 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015996674
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1002/jbmr.1808 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036886575
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1002/jbmr.2442 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016639991
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1002/jbmr.3110 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084012872
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1016/j.bone.2008.04.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010244282
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1016/s0002-9343(97)00249-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023314389
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1056/nejmc062792 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046528061
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1056/nejmoa0809493 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010400337
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1210/jc.2016-3170 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027079529
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1359/jbmr.040305 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040664727
202 rdf:type schema:CreativeWork
203 https://www.grid.ac/institutes/grid.150338.c schema:alternateName University Hospital of Geneva
204 schema:name Service des Maladies Osseuses, Hôpitaux Universitaires et Faculté de Médecine de Genève, 1211, Geneva 14, Switzerland
205 Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
206 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...